Diplomat Pharmacy (DPLO) Says It is Now Filling Prescriptions for ZINBRYTA

August 15, 2016 8:03 AM EDT

Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.

Diplomat Pharmacy, Inc. (NYSE: DPLO) is now filling prescriptions for ZINBRYTA™ (daclizumab), which was recently approved by the Food and Drug Administration. ZINBRYTA is an interleukin-2 receptor-blocking antibody indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (MS)

"A relapse of any kind can cause a person to lose hope," said Gary Kadlec, Diplomat president. "For people with relapsing multiple sclerosis, ZINBRYTA has the potential to restore that hope and make life a little easier."

MS is an unpredictable, often disabling disease of the central nervous system; it interrupts the flow of information within the brain and between the brain and the rest of body. Symptoms include numbness, tingling, blindness, paralysis and cognitive difficulties. According to the National Multiple Sclerosis Society, most people with MS are diagnosed between ages 20 and 50, with at least twice as many women diagnosed as men.

ZINBRYTA is generally reserved for patients who have had an inadequate response to two or more therapies indicated for the treatment of MS.

ZINBRYTA is jointly manufactured by AbbVie, Inc., and Biogen, Inc. Click here for complete ZINBRYTA prescribing information.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Corporate News, FDA, Management Comments

Add Your Comment